NAS:EIDX (USA) Also Trade In: Germany
Eidos Therapeutics Inc $ 122.21 -6.23 (-4.85%)
Warning! GuruFocus has detected 1 Severe warning sign with EIDX. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for EIDX (Eidos Therapeutics Inc) from 2018 to Jan 26 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Eidos Therapeutics stock (EIDX) PE ratio as of Jan 26 2021 is 0. More Details
Eidos Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2018. Start your Free Trial
Eidos Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:CORT NYSE:ZYME NAS:ARVN NAS:XNCR NAS:LGND NAS:IMVT NAS:MDGL NAS:TBPH NAS:SWTX NAS:ZGNX OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.